SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Purpose: The CD38 cell surface antigen is expressed in diverse hematologic malignancies including multiple myeloma, B-cell non-Hodgkin lymphoma (NHL), B-cell chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia (ALL), and T-cell ALL. Here, we assessed the antitumor activity of the anti-CD38 antibody SAR650984. Experimental Design: Activity of SAR650984 was examined on lymphoma, leukemia and multiple myeloma cell lines, primary multiple myeloma samples, and multiple myeloma xenograft models in immunodeficient mice. Results: We identified a humanized anti-CD38 antibody with strong proapoptotic activity independent of cross-linking agents, and potent effector functions including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis (ADCP), equivalent in vitro to rituximab in CD20+ and CD38+ models. This unique antibody, termed SAR650984, inhibited the ADP-ribosyl cyclase activity of CD38, likely through an allosteric antagonism as suggested by 3D structure analysis of the complex. In vivo, SAR650984 was active in diverse NHL, ALL, and multiple myeloma CD38+ tumor xenograft models. SAR650984 demonstrated single-agent activity comparable with rituximab or cyclophosphamide in Daudi or SU-DHL-8 lymphoma xenograft models with induction of the proapoptotic marker cleaved capase-7. In addition, SAR650984 had more potent antitumor activity than bortezomib in NCI-H929 and Molp-8 multiple myeloma xenograft studies. Consistent with its mode of action, SAR650984 demonstrated potent proapoptotic activity against CD38+ human primary multiple myeloma cells. Conclusion: These results validate CD38 as a therapeutic target and support the current evaluation of this unique CD38-targeting functional antibody in phase I clinical trials in patients with CD38+ B-cell malignancies. Clin Cancer Res; 20(17); 4574–83. ©2014 AACR.

[1]  Wei Zheng,et al.  SAR650984, a CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies- Data From a Dose-Escalation Phase I Study , 2013 .

[2]  F. Malavasi,et al.  CD38 and CD157: A long journey from activation markers to multifunctional molecules , 2013, Cytometry. Part B, Clinical cytometry.

[3]  F. Morabito,et al.  Perspectives in the treatment of multiple myeloma , 2013, Expert opinion on biological therapy.

[4]  N. Munshi,et al.  New Strategies in the Treatment of Multiple Myeloma , 2013, Clinical Cancer Research.

[5]  P. Richardson,et al.  Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study , 2012 .

[6]  J. Endell,et al.  The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo , 2012 .

[7]  P. Parren,et al.  Phagocytosis Is A Mechanism of Action for Daratumumab , 2012 .

[8]  Delong Liu,et al.  Novel CD20 monoclonal antibodies for lymphoma therapy , 2012, Journal of Hematology & Oncology.

[9]  P. Richardson,et al.  A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma Preliminary Safety Data , 2011 .

[10]  T. Illidge,et al.  The future of anti-CD20 monoclonal antibodies: are we making progress? , 2011, Blood.

[11]  Kenneth C. Anderson,et al.  Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors , 2011, The Journal of Immunology.

[12]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[13]  Mitchell R. Smith,et al.  Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. , 2010, P & T : a peer-reviewed journal for formulary management.

[14]  Qun Liu,et al.  Conformational Closure of the Catalytic Site of Human CD38 Induced by Calcium. , 2008, Biochemistry.

[15]  M. Tesar.  Fully human antibody MOR202 against CD38 for the treatment of multiple myeloma and other blood-borne malignancies , 2007 .

[16]  S. Deaglio,et al.  CD38/CD19: a lipid raft-dependent signaling complex in human B cells. , 2007, Blood.

[17]  Qun Liu,et al.  Structural Basis for the Mechanistic Understanding of Human CD38-controlled Multiple Catalysis* , 2006, Journal of Biological Chemistry.

[18]  S. Deaglio,et al.  In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. , 2006, Blood.

[19]  Qun Liu,et al.  Crystal structure of human CD38 extracellular domain. , 2005, Structure.

[20]  G. Tricot,et al.  Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. , 2004, American journal of clinical pathology.

[21]  D. Oscier,et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.

[22]  K. Do,et al.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[23]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[24]  A. la Sala,et al.  Functional topography of discrete domains of human CD38. , 2000, Tissue antigens.

[25]  S. Deaglio,et al.  CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[27]  R. Graeff,et al.  Structures and activities of cyclic ADP-ribose, NAADP and their metabolic enzymes , 1999, Molecular and Cellular Biochemistry.

[28]  D. Campana,et al.  CD38-mediated signaling events in murine pro-B cells expressing human CD38 with or without its cytoplasmic domain. , 1999, Journal of immunology.

[29]  F. Malavasi,et al.  The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38 , 1999, Journal of leukocyte biology.

[30]  M. Konopleva,et al.  Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. , 1998, Journal of immunology.

[31]  F. Malavasi,et al.  CD38 is functionally dependent on the TCR/CD3 complex in human T cells , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  F. Schuber,et al.  Human CD38 is an authentic NAD(P)+ glycohydrolase. , 1998, The Biochemical journal.

[33]  V. Mukku,et al.  A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. , 1997, Journal of immunological methods.

[34]  S. Hoshino,et al.  Mapping of the catalytic and epitopic sites of human CD38/NAD+ glycohydrolase to a functional domain in the carboxyl terminus. , 1997, Journal of immunology.

[35]  M. Glennie,et al.  Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. , 1995, Journal of immunology.

[36]  R. Graeff,et al.  Enzymatic synthesis and characterizations of cyclic GDP-ribose. A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity. , 1994, The Journal of biological chemistry.

[37]  Rasmus A. Rasmussen,et al.  Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma [see comments] , 1994 .

[38]  S. Zupo,et al.  CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells , 1994, European journal of immunology.

[39]  A R Rees,et al.  Humanization of murine monoclonal antibodies through variable domain resurfacing. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  P. Lansdorp,et al.  Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. , 1991, Blood.

[41]  T. Hamblin,et al.  Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. , 1991, Blood.

[42]  M. Cooper,et al.  Discontinuous expression of a membrane antigen (HB-7) during B lymphocyte differentiation. , 1984, Tissue antigens.

[43]  E. Reinherz,et al.  Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Sotomayor,et al.  Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. , 2007, Hematology. American Society of Hematology. Education Program.

[45]  T. Hamblin,et al.  Mechanisms in removal of tumor by antibody , 2007, Cell Biophysics.

[46]  M. Konopleva,et al.  CD38 in hematopoietic malignancies. , 2000, Chemical immunology.

[47]  D. Maloney,et al.  Antibody therapy for treatment of multiple myeloma. , 1999, Seminars in hematology.

[48]  R. Graeff,et al.  ADP-ribosyl cyclase and CD38. Multi-functional enzymes in Ca+2 signaling. , 1997, Advances in experimental medicine and biology.

[49]  R. Graeff,et al.  ADP-Ribosyl Cyclase and CD38 , 1997 .